Literature DB >> 8406809

Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.

P L Fidel1, M E Lynch, J D Sobel.   

Abstract

The role of systemic cell-mediated immunity (CMI) as a host defense mechanism in the vagina is poorly understood. Using a murine pseudoestrus model of experimental vaginal candidiasis, we previously found that animals given a vaginal inoculum of viable Candida albicans blastoconidia acquired a persistent vaginal infection and developed Candida-specific delayed-type hypersensitivity (DTH) responses. The present study was designed to characterize the peripheral CMI reactivity generated from the vaginal infection in mice and to determine whether pseudoestrus is a prerequisite for the induction of peripheral CMI reactivity. Mice treated or not treated with estrogen and given a vaginal inoculum of C. albicans blastoconidia were examined for 4 weeks for their vaginal Candida burden and peripheral CMI reactivity, including DTH responsiveness and in vitro Th1 (interleukin-2 [IL-2], gamma interferon [IFN-gamma]/Th2 (IL-4, IL-10)-type lymphokine production in response to Candida antigens. Results showed that although mice not treated with estrogen before being given a vaginal inoculum of C. albicans blastoconidia developed only a short-lived vaginal infection and harbored significantly fewer Candida CFU in the vagina compared with those given estrogen and then infected; DTH reactivity was equivalent in both groups. In vitro measurement of CMI reactivity further showed that lymph node cells from both estrogen- and non-estrogen-treated infected mice produced elevated levels of IL-2 and IFN-gamma in response to Candida antigens during the 4 weeks after vaginal inoculation. In contrast, lymph node cells from the same vaginally infected mice showed no IL-10 production and only small elevations of IL-4 during week 4 of infection. These results suggest that mice with experimental vaginal candidiasis develop predominantly Th1-type Candida-specific peripheral CMI reactivity and that similar patterns of Th1-type reactivity occur in mice regardless of the persistence of infection and the estrogen status of the infected mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406809      PMCID: PMC281145          DOI: 10.1128/iai.61.10.4202-4207.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.

Authors:  J E Domer; R E Garner; R N Befidi-Mengue
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

2.  Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S).

Authors:  J Hu-Li; J Ohara; C Watson; W Tsang; W E Paul
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

3.  Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.

Authors:  T F Gajewski; F W Fitch
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

Review 4.  A functional dichotomy in CD4+ T lymphocytes.

Authors:  K Bottomly
Journal:  Immunol Today       Date:  1988-09

Review 5.  Pathogenesis and epidemiology of vulvovaginal candidiasis.

Authors:  J D Sobel
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

6.  Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans.

Authors:  S S Witkin
Journal:  Obstet Gynecol       Date:  1986-11       Impact factor: 7.661

7.  Quantification of vaginal Candida albicans infections in rodents.

Authors:  J F Ryley; S McGregor
Journal:  J Med Vet Mycol       Date:  1986-12

8.  Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis.

Authors:  A Durandy; A Fischer; F Le Deist; E Drouhet; C Griscelli
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

9.  Inhibition of B lymphocyte activation by interferon-gamma.

Authors:  D S Reynolds; W H Boom; A K Abbas
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

10.  A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors.

Authors:  S S Witkin; J Hirsch; W J Ledger
Journal:  Am J Obstet Gynecol       Date:  1986-10       Impact factor: 8.661

View more
  39 in total

1.  Evidence for a unique expression of CD4 on murine vaginal CD4+ cells.

Authors:  F L Wormley; M Scott; W Luo; M Baker; J Chaiban; P L Fidel
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

2.  Deletion of the two-component histidine kinase gene (CHK1) of Candida albicans contributes to enhanced growth inhibition and killing by human neutrophils in vitro.

Authors:  Antonella Torosantucci; Paola Chiani; Flavia De Bernardis; Antonio Cassone; Jose Antonio Calera; Richard Calderone
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans.

Authors:  Shinji Kagami; Heather L Rizzo; Stephen E Kurtz; Lloyd S Miller; Andrew Blauvelt
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

4.  Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.

Authors:  F L Wormley; J Chaiban; P L Fidel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

5.  Candida albicans-derived beta-1,2-linked mannooligosaccharides induce desensitization of macrophages.

Authors:  T Jouault; C Fradin; P A Trinel; D Poulain
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

6.  Effects of reproductive hormones on experimental vaginal candidiasis.

Authors:  P L Fidel; J Cutright; C Steele
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 7.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

8.  CD86 (B7-2), but not CD80 (B7-1), expression in the epidermis of transgenic mice enhances the immunogenicity of primary cutaneous Candida albicans infections.

Authors:  A A Gaspari; R Burns; A Nasir; D Ramirez; R K Barth; C G Haidaris
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Authors:  Y Han; R P Morrison; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Candida-specific antibodies during experimental vaginal candidiasis in mice.

Authors:  Karen L Wozniak; Floyd L Wormley; Paul L Fidel
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.